Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-Q Quarterly report for the period ending Saturday, March 31, 2018

Aclaris Therapeutics, Inc.

CIK: 1557746 Ticker: ACRS

Exhibit 99.1

 

Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

·

Management to Host Conference Call at 5:00 PM ET today

 

 

Wayne, PA – May 8, 2018 (GLOBE NEWSWIRE) –

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology, today announced financial results for the first quarter 2018 and provided an update on its clinical development and commercial programs.   

“The first quarter of 2018 was a busy one as we prepared for the launch of ESKATA™ (hydrogen peroxide) Topical Solution, 40% (w/w), the first and only FDA-approved topical treatment for raised seborrheic keratosis (SK). We held the ESKATA Launch Meeting last week, and ESKATA is now officially available for physicians and their patients,” said Brett Fair, Chief Commercial Officer of Aclaris.

 

Commercial Update:

·

Successful rollout and implementation of the ESKATA Early Experience Initiative (EEI).

o

Program expanded to over 700 accounts to accommodate market demand for ESKATA.

o

Ongoing in-service programs to support successful training and product integration.

o

Positive initial ESKATA feedback from EEI program captured in physician and patient post-application surveys.

·

Aclaris sales force successful in generating a significant number of ESKATA pre-orders from targeted accounts ahead of official launch meeting.

o

Commenced health care provider (HCP) order processing and shipping the week of April 23, 2018.

·

ESKATA Launch Campaign Highlights:

o

ESKATA Launch Meeting held April 30 – May 4, 2018; Unveiled New ESKATA Campaign; sales force trained on new tools and resources to support a successful ESKATA launch.

o

ESKATA Consumer website (www.eskata.com) launched May 1, 2018; includes “Find A Doctor” resource for patients seeking ESKATA treatment.

 


The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Tuesday, May 8, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Operations And Comprehensive Loss (parenthetical)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Acquisition Of Confluence
Acquisition Of Confluence (tables)
Acquisition Of Confluence - Summary Of Fair Value Consideration (details)
Acquisition Of Confluence - Supplemental Pro Forma Financial Information (details)
Agreements Related To Intellectual Property
Agreements Related To Intellectual Property (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (detail)
Fair Value Of Financial Assets And Liabilities (tables)
Fair Value Of Financial Assets And Liabilities - By Type (details)
Income Taxes
Income Taxes - Rate Reconciliation (details)
Net Loss Per Share
Net Loss Per Share (details)
Net Loss Per Share (tables)
Net Loss Per Share - Anti-dilution (details)
Organization And Nature Of Business
Organization And Nature Of Business (details)
Property And Equipment, Net
Property And Equipment, Net (details)
Property And Equipment, Net (tables)
Related Party Transactions
Related Party Transactions (details)
Related Party Transactions (tables)
Segments
Segments (details)
Segments (tables)
Stock-based Awards
Stock-based Awards (details)
Stock-based Awards (tables)
Stock-based Awards - Compensation (details)
Stock-based Awards - Option Activity (details)
Stock-based Awards - Rsus (details)
Stockholders' Equity
Stockholders' Equity (details)
Stockholders' Equity - Ipo, Etc. (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies - Goodwill, Segments (details)
Summary Of Significant Accounting Policies - Recent Pronouncements (details)

Material Contracts, Statements, Certifications & more

Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ACRS
CIK: 1557746
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-18-004349
Submitted to the SEC: Tue May 08 2018 5:15:48 PM EST
Accepted by the SEC: Tue May 08 2018
Period: Saturday, March 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-18-004349.htm